Dillard R D, Bach N J, Draheim S E, Berry D R, Carlson D G, Chirgadze N Y, Clawson D K, Hartley L W, Johnson L M, Jones N D, McKinney E R, Mihelich E D, Olkowski J L, Schevitz R W, Smith A C, Snyder D W, Sommers C D, Wery J P
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
J Med Chem. 1996 Dec 20;39(26):5137-58. doi: 10.1021/jm960486n.
As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A2(hnps-PLA2) was developed. The design of these compounds was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.
正如我们之前的论文所报道的,我们开发了一系列具有作为人非胰腺分泌型磷脂酶A2(hnps-PLA2)抑制剂的效力和选择性的吲哚-3-乙酰胺。这些化合物的设计基于从该酶与其抑制剂之间的复合物的X射线晶体结构获得的信息。我们在此描述这种基于结构的设计策略的进一步实施以及持续的构效关系(SAR)开发,以产生具有额外功能基团的吲哚-3-乙酰胺,这些功能基团能增加与酶活性位点内重要残基的相互作用。这些努力产生了效力和选择性显著增强的抑制剂。